Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy
- PMID: 14996105
- DOI: 10.1111/j.1365-2133.2004.05712.x
Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy
Abstract
Background: Purine analogues [fludarabine monophosphate (FAMP); deoxycoformycin and 2-chlorodeoxyadenosine) and extracorporeal photochemotherapy (ECP) have been suggested to be active agents in advanced cutaneous T-cell lymphoma (CTCL) patients.
Objectives: To explore further the clinical efficacy and safety of FAMP monochemotherapy in advanced CTCL and to evaluate if the sequential association of ECP to FAMP in selected patients may improve the response rate (RR) and/or lengthen the remission duration.
Patients and methods: Forty-four CTCL patients [17 Sézary syndrome (SS); 26 mycosis fungoides (MF), stage IIB-IV or with peripheral blood involvement; one MF associated with lymphomatoid papulosis (LyP)] were enrolled in this pilot cohort study. All the patients received FAMP 25 mg m(-2) 5 days monthly; 19 patients (43.2%) underwent ECP after FAMP was discontinued. The majority of patients with erythrodermic CTCL or peripheral blood involvement underwent the combined FAMP-ECP schedule.
Results: After a median follow-up of 4.2 years, the overall FAMP RR was 29.5% (13/44); a higher RR was obtained in SS (35.3%) than in MF patients (25.9%). According to the treatment group, the RR of the FAMP-ECP group (63.2%) was significantly higher than that of the FAMP monotherapy group (24%; P=0.021). No statistically significant difference was found in time-to-progression (TTP) or survival by therapy group, even if the TTP of the patients treated with the FAMP-ECP combination therapy was higher (median 13 vs. 7 months). A decrease or a normalization in the CD4+CD26- circulating subset was observed in responding patients, paralleling the reduction in the circulating Sézary cells.
Conclusions: FAMP confirms its clinical activity as a single agent in SS; conversely, FAMP results do not compare favourably with other therapeutic approaches for advanced stage MF patients. The sequential association of ECP after FAMP seems to increase the RR, even if future randomized studies are needed to confirm these results.
Similar articles
-
Extracorporeal photophoresis: an evidence-based analysis.Ont Health Technol Assess Ser. 2006;6(6):1-82. Epub 2006 Mar 1. Ont Health Technol Assess Ser. 2006. PMID: 23074497 Free PMC article.
-
Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.Dermatol Clin. 2015 Oct;33(4):765-76. doi: 10.1016/j.det.2015.05.011. Epub 2015 Jul 29. Dermatol Clin. 2015. PMID: 26433848 Review.
-
Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.Arch Dermatol. 2002 Oct;138(10):1347-50. doi: 10.1001/archderm.138.10.1347. Arch Dermatol. 2002. PMID: 12374541
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2. doi: 10.1016/j.jaad.2013.08.033. J Am Acad Dermatol. 2014. PMID: 24438970 Review.
-
Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.Int J Dermatol. 2013 Nov;52(11):1308-18. doi: 10.1111/ijd.12121. Epub 2013 Jun 20. Int J Dermatol. 2013. PMID: 23786842 Review.
Cited by
-
Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.Leuk Lymphoma. 2008 Jun;49(6):1190-201. doi: 10.1080/10428190802064917. Leuk Lymphoma. 2008. PMID: 18569641 Free PMC article.
-
Clinical Results of Extracorporeal Photopheresis.Transfus Med Hemother. 2012 Aug;39(4):254-262. doi: 10.1159/000341811. Epub 2012 Jul 26. Transfus Med Hemother. 2012. PMID: 22969695 Free PMC article.
-
European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2693-2716. doi: 10.1111/jdv.16890. Epub 2020 Oct 6. J Eur Acad Dermatol Venereol. 2020. PMID: 33025659 Free PMC article.
-
Guidelines on the use of extracorporeal photopheresis.J Eur Acad Dermatol Venereol. 2014 Jan;28 Suppl 1(Suppl 1):1-37. doi: 10.1111/jdv.12311. J Eur Acad Dermatol Venereol. 2014. PMID: 24354653 Free PMC article.
-
Extracorporeal photophoresis: an evidence-based analysis.Ont Health Technol Assess Ser. 2006;6(6):1-82. Epub 2006 Mar 1. Ont Health Technol Assess Ser. 2006. PMID: 23074497 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous